Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
IGF-1 treatment: future and limitations The FDA approved the use of rhIGF-1 (Mecasermin, Increlex) for treatment of severe primary IGF-1 deficiency in 2003
SEQUENCE: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
## Combining Semaglutide with Supportive Therapies One advantage of transitioning from AOD-9604 to a GLP-1 **weight loss peptide** is the ability to complement the protocol with well-studied supportive therapies: ### NAD+ for Metabolic and Anti-Aging Support [NAD+ injections](/guides/nad-injection-benefits-anti-aging-energy-recovery-guide) support mitochondrial function, cellular energy production, and DNA repair all of which may be beneficial during active **fat loss**
Researchers proposed a direct correlation between the reduction in adiposity and the augmented expression of these receptors in laboratory settings
Weekly injections for the first 4 to 6 weeks are ideal for patients who are deficient and want to build their levels up quickly
